1473 / 1816
RAPCHEM study (
NCT01279304
)
cT1-2N1 ( > 3 suspicious nodes excluded), treated with PST
•
Group I low risk: ypT0-2
N0
:
•
after MRM: no RT; after BCT: RT breast
•
If SN/MARI is negative: no RT
•
Group II intermediate risk: ypT0-2
N1
:
•
after MRM: RT thoracic wall; after BCT: RT of breast
•
if SN/MARI micromets and no RF: add RT of the axilla level 1&2
•
Group III high risk: ypT0-2
N≥2
:
•
RT thoracic wall/ breast
and
periclavicular nodes.
•
if SN/MARI shows metastasis, add RT of the axilla1&2 or perform
ALND.
RT of the axillary and internal mammary chain nodes is optional. Each
participating centre should state their treatment policy on beforehand.